These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 30069716)
1. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature. Borrill R; Cheesman E; Stivaros S; Kamaly-Asl ID; Gnanalingham K; Kilday JP Childs Nerv Syst; 2019 Jan; 35(1):169-173. PubMed ID: 30069716 [TBL] [Abstract][Full Text] [Related]
2. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas. Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946 [TBL] [Abstract][Full Text] [Related]
3. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733 [TBL] [Abstract][Full Text] [Related]
5. Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift. Nussbaum PE; Nussbaum LA; Torok CM; Patel PD; Yesavage TA; Nussbaum ES J Clin Pharm Ther; 2022 Jun; 47(6):826-831. PubMed ID: 35023192 [TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature. Losa M; Mazza E; Pedone E; Nocera G; Liscia N; Reni M; Mortini P J Endocrinol Invest; 2024 Nov; 47(11):2835-2842. PubMed ID: 38696125 [TBL] [Abstract][Full Text] [Related]
7. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma]. Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087 [No Abstract] [Full Text] [Related]
8. Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features. Yue Q; Yu Y; Shi Z; Wang Y; Zhu W; Du Z; Yao Z; Chen L; Mao Y J Neurosurg; 2018 Jul; 129(1):27-34. PubMed ID: 28984520 [TBL] [Abstract][Full Text] [Related]
9. BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts. Schweizer L; Capper D; Hölsken A; Fahlbusch R; Flitsch J; Buchfelder M; Herold-Mende C; von Deimling A; Buslei R Neuropathol Appl Neurobiol; 2015 Oct; 41(6):733-42. PubMed ID: 25442675 [TBL] [Abstract][Full Text] [Related]
10. BRAF V600E mutation is a useful marker for differentiating Rathke's cleft cyst with squamous metaplasia from papillary craniopharyngioma. Kim JH; Paulus W; Heim S J Neurooncol; 2015 May; 123(1):189-91. PubMed ID: 25820214 [No Abstract] [Full Text] [Related]
11. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma? Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631 [TBL] [Abstract][Full Text] [Related]
12. Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review. Yu N; Raslan OA; Lee HS; Theeler BJ; Raafat TA; Fragoso R; Shahlaie K; Aboud O CNS Oncol; 2024 Jan; 13(1):CNS106. PubMed ID: 38348829 [TBL] [Abstract][Full Text] [Related]
13. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106 [No Abstract] [Full Text] [Related]
14. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. Brastianos PK; Shankar GM; Gill CM; Taylor-Weiner A; Nayyar N; Panka DJ; Sullivan RJ; Frederick DT; Abedalthagafi M; Jones PS; Dunn IF; Nahed BV; Romero JM; Louis DN; Getz G; Cahill DP; Santagata S; Curry WT; Barker FG J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26498373 [TBL] [Abstract][Full Text] [Related]
15. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. Roque A; Odia Y CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764 [TBL] [Abstract][Full Text] [Related]
17. Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation. Xu C; Ge S; Cheng J; Gao H; Zhang F; Han A Front Endocrinol (Lausanne); 2022; 13():859381. PubMed ID: 35707464 [TBL] [Abstract][Full Text] [Related]
18. Optic tract edema in craniopharyngioma as a predictor of BRAFV600E mutation presence. Taguchi A; Kinoshita Y; Kojima M; Amatya VJ; Tominaga A; Takeshima Y; Arita K; Hiyama E; Yamasaki F; Horie N Jpn J Clin Oncol; 2023 Apr; 53(5):378-385. PubMed ID: 36702745 [TBL] [Abstract][Full Text] [Related]